Price
CHART BY
Frequently asked questions
What is Illumina's market capitalization?
The market capitalization of Illumina is $37.22B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is Illumina's Price-to-Earnings (P/E) ratio?
The Price-to-Earnings (P/E) ratio (TTM) for Illumina is 45.94. This ratio helps investors assess whether a stock is overvalued or undervalued compared to its earnings.
What is the Earnings Per Share (EPS) for Illumina?
Illumina's Earnings Per Share (EPS) over the trailing twelve months (TTM) is $5.366. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Illumina's stock?
Currently, 24 analysts cover Illumina's stock, with a consensus target price of $204.63. Analyst ratings provide insights into the stock's expected performance.
What is Illumina's revenue over the trailing twelve months?
Over the trailing twelve months, Illumina reported a revenue of $4.50B.
What is the EBITDA for Illumina?
Illumina's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is $1.17B. EBITDA measures the company's overall financial performance.
What is the free cash flow of Illumina?
Illumina has a free cash flow of $931.00M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Illumina have, and what sector and industry does it belong to?
Illumina employs approximately 8,600 people. It operates in the Health Care sector, specifically within the Medical Specialties industry.
What is the free float of Illumina's shares?
The free float of Illumina is 150.55M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $37.22B
- EPS (TTM)
- $5.366
- Free Float
- 150.55M
- P/E ratio (TTM)
- 45.94
- Revenue (TTM)
- $4.50B
- EBITDA (TTM)
- $1.17B
- Free Cashflow (TTM)
- $931.00M
Pricing
- 1D span
- $252.19$268.85
- 52W span
- $88.00$256.16
Analyst Ratings
The price target is $204.63 and the stock is covered by 24 analysts.
Buy
12
Hold
8
Sell
4
Information
Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. The company was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock, and Mark S. Chee in April 1998 and is headquartered in San Diego, CA.
- Employees
- 8,600
- Industries
- Medical Specialties
- Sector
- Health Care
Identifier
- Primary Ticker
- ILMN
Knockouts
Real-time data from LSX · Fundamentals & EOD data from FactSet